TWST · Twist Bioscience Corporation
$139.92
+3.29% last session
End-of-day data · close of 2026-10-23
Market cap
$9B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-349.8
Dividend yield
0.0%
Beta
2.19
Avg volume
2M
Employees
1K
Daily Change %
3.29%
5 Days Change
2.05%
10 Days Change
-10.48%
30 Days Change
-14.53%
60 Days Change
-3.79%
Month to Day Change
-27.96%
Year to Day Change
327.08%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TWST
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-13
Latest call per bank · past 12 months
Jefferies
Hold$150
+7.2% vs priceBarclays
Overweight$215
+53.7% vs priceUBS
Neutral$144
+2.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Maintains | Buy | $115 → $190 |
| 2026-10-12 | Canaccord Genuity | Maintains | Buy | $120 → $205 |
| 2026-10-08 | Jefferies | Initiates | Hold | $0.00 → $150 |
| 2026-10-07 | Barclays | Maintains | Overweight | $112 → $215 |
| 2026-10-01 | Guggenheim | Maintains | Buy | $107 → $212 |
| 2026-09-29 | Leerink Partners | Maintains | Outperform | $160 → $190 |
| 2026-09-18 | BWS Financial | Maintains | Sell | $45.00 |
| 2026-09-17 | Leerink Partners | Maintains | Outperform | $120 → $160 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 6.6% below the 50-day MA ($149.77).
- bullish: Price vs 200-day MA: Trading 62.8% above the 200-day MA ($85.93).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-3.64) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($25.45) and high ($205.00).
TWST Price Chart
Loading chart for TWST…
Fundamentals
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.